← Back to Search

Hormone Therapy

Insulin Therapy After Cardiac Surgery

N/A
Waitlist Available
Led By Roupen Hatzakorzian, MD
Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up eight hours after the end of surgery
Awards & highlights

Study Summary

This trial will investigate the effect of high-dose insulin therapy on protein, glucose, and end-organ metabolism in patients undergoing CABG surgery.

Who is the study for?
This trial is for patients who can consent and are undergoing elective cardiac surgery, specifically CABG. It's not suitable for those with severe malnutrition or obesity (BMI <20 or >30), significant weight loss in the past six months, or chronic liver failure.Check my eligibility
What is being tested?
The study tests high-dose insulin therapy on protein and glucose metabolism during CABG surgery. Patients will be split into two groups: one receiving standard insulin to keep blood sugar under control, and another getting a high dose of insulin plus glucose to maintain normal blood sugar levels.See study design
What are the potential side effects?
While specific side effects aren't listed, potential risks may include low blood sugar due to high-dose insulin therapy, which could cause shakiness, sweating, confusion, heart palpitations or even loss of consciousness if severe.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~eight hours after the end of surgery
This trial's timeline: 3 weeks for screening, Varies for treatment, and eight hours after the end of surgery for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Protein breakdown

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: High-dose insulinExperimental Treatment1 Intervention
Group II: ControlActive Control1 Intervention

Find a Location

Who is running the clinical trial?

McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor
451 Previous Clinical Trials
161,836 Total Patients Enrolled
Roupen Hatzakorzian, MDPrincipal InvestigatorMcGill University Health Centre/Research Institute of the McGill University Health Centre

Media Library

Regular human insulin injection (Hormone Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT01601561 — N/A
Cardiac Surgery Research Study Groups: High-dose insulin, Control
Cardiac Surgery Clinical Trial 2023: Regular human insulin injection Highlights & Side Effects. Trial Name: NCT01601561 — N/A
Regular human insulin injection (Hormone Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01601561 — N/A
~2 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top